OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
Dorin Toader, Shawn P. Fessler, Scott D. Collins, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 9, pp. 999-1012
Open Access | Times Cited: 18
Dorin Toader, Shawn P. Fessler, Scott D. Collins, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 9, pp. 999-1012
Open Access | Times Cited: 18
Showing 18 citing articles:
Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates
Tomohiro Watanabe, Naoko Arashida, Tomohiro Fujii, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 20, pp. 18124-18138
Open Access | Times Cited: 9
Tomohiro Watanabe, Naoko Arashida, Tomohiro Fujii, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 20, pp. 18124-18138
Open Access | Times Cited: 9
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry
Tomohiro Fujii, Yutaka Matsuda
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 11, pp. 1053-1065
Closed Access | Times Cited: 14
Tomohiro Fujii, Yutaka Matsuda
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 11, pp. 1053-1065
Closed Access | Times Cited: 14
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models
Elizabeth Gray, Michelle Ulrich, Angela Epp, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 10, pp. e007572-e007572
Open Access | Times Cited: 13
Elizabeth Gray, Michelle Ulrich, Angela Epp, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 10, pp. e007572-e007572
Open Access | Times Cited: 13
Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing
Tess A. O’Meara, Paolo Tarantino, Stefania Morganti, et al.
Current Oncology Reports (2025)
Closed Access
Tess A. O’Meara, Paolo Tarantino, Stefania Morganti, et al.
Current Oncology Reports (2025)
Closed Access
Development of Antibody–Drug Conjugates for Malignancies of the Uterine Corpus: A Review
T. Yamanaka, Tadaaki Nishikawa, Hiroshi Yoshida
Cells (2025) Vol. 14, Iss. 5, pp. 333-333
Open Access
T. Yamanaka, Tadaaki Nishikawa, Hiroshi Yoshida
Cells (2025) Vol. 14, Iss. 5, pp. 333-333
Open Access
INFLUENCE OF DRUG DELIVERY SYSTEMS ON THE SAFETY AND EFFECTIVENESS PROFILE OF RIBAVIRIN
Iosif B. Mikhel, S. A. TITOVA, Е. О. Бахрушина, et al.
International Journal of Applied Pharmaceutics (2025), pp. 65-77
Open Access
Iosif B. Mikhel, S. A. TITOVA, Е. О. Бахрушина, et al.
International Journal of Applied Pharmaceutics (2025), pp. 65-77
Open Access
B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review
Marion Phipps, Gerald S. Falchook
Journal of Immunotherapy and Precision Oncology (2025) Vol. 8, Iss. 2, pp. 153-160
Open Access
Marion Phipps, Gerald S. Falchook
Journal of Immunotherapy and Precision Oncology (2025) Vol. 8, Iss. 2, pp. 153-160
Open Access
Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development
Qi Ma, Puro Durga, Frederick X.C. Wang, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 8, pp. 104057-104057
Closed Access | Times Cited: 4
Qi Ma, Puro Durga, Frederick X.C. Wang, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 8, pp. 104057-104057
Closed Access | Times Cited: 4
The treatment landscape of triple-negative breast cancer
Yi Hu, Chen Wang, Huishi Liang, et al.
Medical Oncology (2024) Vol. 41, Iss. 10
Closed Access | Times Cited: 4
Yi Hu, Chen Wang, Huishi Liang, et al.
Medical Oncology (2024) Vol. 41, Iss. 10
Closed Access | Times Cited: 4
B7-H4 Protein Expression in Endometrial Cancer
Bobby L. May, Nicholas Conway, Tracy Truong, et al.
(2025)
Closed Access
Bobby L. May, Nicholas Conway, Tracy Truong, et al.
(2025)
Closed Access
The clinical landscape of antibody-drug conjugates in endometrial cancer
Giovanni Fucá, Ilaria Sabatucci, Mariachiara Paderno, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 11, pp. 1795-1804
Closed Access | Times Cited: 3
Giovanni Fucá, Ilaria Sabatucci, Mariachiara Paderno, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 11, pp. 1795-1804
Closed Access | Times Cited: 3
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Elizabeth C. Wescott, Xiaopeng Sun, Paula I. González-Ericsson, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 4, pp. 1120-1134
Open Access | Times Cited: 2
Elizabeth C. Wescott, Xiaopeng Sun, Paula I. González-Ericsson, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 4, pp. 1120-1134
Open Access | Times Cited: 2
B7H4 Role in Solid Cancers: A Review of the Literature
Miriam Dawidowicz, Anna Kot, Sylwia Mielcarska, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2519-2519
Open Access | Times Cited: 2
Miriam Dawidowicz, Anna Kot, Sylwia Mielcarska, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2519-2519
Open Access | Times Cited: 2
Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Susan M. Clardy, Alex Uttard, Bingfan Du, et al.
Molecular Cancer Therapeutics (2023) Vol. 23, Iss. 1, pp. 84-91
Closed Access | Times Cited: 5
Susan M. Clardy, Alex Uttard, Bingfan Du, et al.
Molecular Cancer Therapeutics (2023) Vol. 23, Iss. 1, pp. 84-91
Closed Access | Times Cited: 5
The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives
Lu Zhou, Yuanqiong Duan, Kaiyu Fu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Lu Zhou, Yuanqiong Duan, Kaiyu Fu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs
Abhik Mukherjee, Debasish Bandyopadhyay
Cancers (2024) Vol. 16, Iss. 20, pp. 3517-3517
Open Access | Times Cited: 1
Abhik Mukherjee, Debasish Bandyopadhyay
Cancers (2024) Vol. 16, Iss. 20, pp. 3517-3517
Open Access | Times Cited: 1
Exo-Cleavable Linkers: A Paradigm Shift for Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
Tomohiro Watanabe, Naoko Arashida, Tomohiro Fujii, et al.
(2023)
Open Access | Times Cited: 3
Tomohiro Watanabe, Naoko Arashida, Tomohiro Fujii, et al.
(2023)
Open Access | Times Cited: 3
Technical, Preclinical, and Clinical Developments of Fc Glycan-Specific Antibody-drug Conjugates
Qiang Yang, Yunpeng Liu
RSC Medicinal Chemistry (2024)
Open Access
Qiang Yang, Yunpeng Liu
RSC Medicinal Chemistry (2024)
Open Access
Nucleic acid‐based small molecules as targeted transcription therapeutics for immunoregulation
Dan Bai, Reihane Ziadlou, Thangavel Vaijayanthi, et al.
Allergy (2023) Vol. 79, Iss. 4, pp. 843-860
Open Access
Dan Bai, Reihane Ziadlou, Thangavel Vaijayanthi, et al.
Allergy (2023) Vol. 79, Iss. 4, pp. 843-860
Open Access
